Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?-Reference-Cited by-同舟云学术

Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?

Published:2022-02-06 Issue:3 Volume:192 Page:465-484
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Morganti Stefania,Marra Antonio,Crimini Edoardo,D’Amico Paolo,Zagami Paola,Curigliano Giuseppe^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-022-06535-1.pdf

Reference111 articles.

1. Abrams JS (2001) Adjuvant therapy for breast cancer–results from the USA consensus conference. Breast Cancer 8(4):298–304. https://doi.org/10.1007/BF02967528

2. Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444. https://doi.org/10.1016/S0140-6736(11)61625-5

3. Early Breast Cancer Trialists’ Collaborative G (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 393(10179):1440–1452. https://doi.org/10.1016/S0140-6736(18)33137-4

4. Baum M, Brinkley DM, Dossett JA (1983) Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1(8319):257–261

5. Breast International Group 1-98 Collaborative G, Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757. https://doi.org/10.1056/NEJMoa052258

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of lineage-specific epigenetic regulators FOXA1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines;Cancer Gene Therapy;2024-03-01

2. Multimodal histopathologic models stratify hormone receptor-positive early breast cancer;2024-02-28

3. Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception;Clinical Cancer Research;2023-09-01

4. Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility;British Journal of Cancer;2023-02-01

5. Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer;Cancer Treatment and Research;2023